Rapamycin and Alzheimer’s disease: Time for a clinical trial?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rapamycin and Alzheimer’s disease: Time for a clinical trial?

Published:2019-01-23 Issue:476 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kaeberlein Matt¹^ORCID,Galvan Veronica²³^ORCID

Affiliation:

1. Department of Pathology, University of Washington, Seattle, WA 98045, USA.

2. Department of Cellular and Integrative Physiology, Barshop Institute for Longevity and Aging Studies and Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX 78229, USA.

3. Department of Veterans Affairs, South Texas Veterans Health Care System and Geriatric Research Education and Clinical Center, San Antonio, TX 78229, USA.

Abstract

In this Perspective, the authors propose that clinical testing of rapamycin in patients with Alzheimer’s disease is long overdue.

Funder

National Institute on Aging

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference41 articles.

1. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention

2. Healthy aging: The ultimate preventative medicine

3. The Hallmarks of Aging

4. Translational geroscience: A new paradigm for 21st century medicine

5. Modulating mTOR in Aging and Health

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Usnic Acid Analogue 4-FPBUA Enhances the Blood–Brain Barrier Function and Induces Autophagy in Alzheimer’s Disease Mouse Models;ACS Chemical Neuroscience;2024-08-15

2. Adenosine A2A Receptor Antagonist Sch58261 Improves the Cognitive Function in Alzheimer’s Disease Model Mice Through Activation of Nrf2 via an Autophagy-Dependent Pathway;Antioxidants & Redox Signaling;2024-07-08

3. Neuroimmune Dysfunction in Alzheimer’s Disease and Other Forms of Dementia;Chemical and Pharmaceutical Bulletin;2024-07-01

4. Path-based reasoning for biomedical knowledge graphs with BioPathNet;2024-06-18

5. Metabolic syndrome and neuroprotection;SCT Proceedings in Interdisciplinary Insights and Innovations;2024-06-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3